Skip to main content
PMC home page
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1989 Jan;96(1):111–116. doi: 10.1111/j.1476-5381.1989.tb11790.x

Role of endoperoxides in arachidonic acid-induced vasoconstriction in the isolated perfused kidney of the rat.

J Quilley 1, J C McGiff 1, A Nasjletti 1
PMCID: PMC1854306  PMID: 2522332

Abstract

1. Administration of arachidonic acid caused dose-dependent vasoconstriction in the isolated rat kidney perfused in situ with Krebs-Henseleit solution. 2. Inhibition of cyclo-oxygenase with indomethacin or meclofenamate reduced the renal vasoconstrictor effect of arachidonic acid. 3. The renal vasoconstrictor effect of arachidonic acid was unaffected by CGS-13080 at concentrations that effectively reduced thromboxane A2 (TxA2) synthesis by platelets and the kidney. 4. The endoperoxide/TxA2 receptor antagonist, SQ 29,548, abolished the renal vasoconstrictor effect of arachidonic acid and of U46619, an endoperoxide analogue. In contrast, SQ 29,548 did not affect the renal vasoconstrictor response to angiotensin II, prostaglandin E2 or F2 alpha. 5. These data suggest that the vasoconstrictor effect of arachidonic acid in the isolated kidney of the rat is mediated by its metabolites, including the prostaglandin endoperoxides.

Full text

PDF

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Chang L. C., Splawinski J. A., Oates J. A., Nies A. S. Enhanced renal prostaglandin production in the dog. II. Effects on intrarenal hemodynamics. Circ Res. 1975 Jan;36(1):204–207. doi: 10.1161/01.res.36.1.204. [DOI] [PubMed] [Google Scholar]
  2. Coleman R. A., Humphrey P. P., Kennedy I., Levy G. P., Lumley P. Comparison of the actions of U-46619, a prostaglandin H2-analogue, with those of prostaglandin H2 and thromboxane A2 on some isolated smooth muscle preparations. Br J Pharmacol. 1981 Jul;73(3):773–778. doi: 10.1111/j.1476-5381.1981.tb16814.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Flower R. J. Drugs which inhibit prostaglandin biosynthesis. Pharmacol Rev. 1974 Mar;26(1):33–67. [PubMed] [Google Scholar]
  4. Garcia-Szabo R., Kern D. F., Malik A. B. Pulmonary vascular response to thrombin: effects of thromboxane synthetase inhibition with OKY-046 and OKY-1581. Prostaglandins. 1984 Dec;28(6):851–866. doi: 10.1016/0090-6980(84)90039-x. [DOI] [PubMed] [Google Scholar]
  5. Gerber J. G., Nies A. S. The hemodynamic effects of prostaglandins in the rat. Evidence for important species variation in renovascular responses. Circ Res. 1979 Mar;44(3):406–410. doi: 10.1161/01.res.44.3.406. [DOI] [PubMed] [Google Scholar]
  6. Larsson C., Anggård E. Increased juxtamedullary blood flow on stimulation of intrarenal prostaglandin biosynthesis. Eur J Pharmacol. 1974 Mar;25(3):326–334. doi: 10.1016/0014-2999(74)90263-5. [DOI] [PubMed] [Google Scholar]
  7. MacNab M. W., Foltz E. L., Graves B. S., Rinehart R. K., Tripp S. L., Feliciano N. R., Sen S. The effects of a new thromboxane synthetase inhibitor, CGS-13080, in man. J Clin Pharmacol. 1984 Feb-Mar;24(2-3):76–83. doi: 10.1002/j.1552-4604.1984.tb02768.x. [DOI] [PubMed] [Google Scholar]
  8. Malik K. U., McGiff J. C. Modulation by prostaglandins of adrenergic transmission in the isolated perfused rabbit and rat kidney. Circ Res. 1975 May;36(5):599–609. doi: 10.1161/01.res.36.5.599. [DOI] [PubMed] [Google Scholar]
  9. Ogletree M. L., Harris D. N., Greenberg R., Haslanger M. F., Nakane M. Pharmacological actions of SQ 29,548, a novel selective thromboxane antagonist. J Pharmacol Exp Ther. 1985 Aug;234(2):435–441. [PubMed] [Google Scholar]
  10. Powell W. S. Rapid extraction of oxygenated metabolites of arachidonic acid from biological samples using octadecylsilyl silica. Prostaglandins. 1980 Nov;20(5):947–957. doi: 10.1016/0090-6980(80)90144-6. [DOI] [PubMed] [Google Scholar]
  11. Sakr H. M., Dunham E. W. Mechanism of arachidonic acid-induced vasoconstriction in the intact rat kidney: possible involvement of thromboxane A2. J Pharmacol Exp Ther. 1982 Jun;221(3):614–622. [PubMed] [Google Scholar]
  12. Saussy D. L., Jr, Mais D. E., Knapp D. R., Halushka P. V. Thromboxane A2 and prostaglandin endoperoxide receptors in platelets and vascular smooth muscle. Circulation. 1985 Dec;72(6):1202–1207. doi: 10.1161/01.cir.72.6.1202. [DOI] [PubMed] [Google Scholar]
  13. Shibouta Y., Terashita Z. I., Inada Y., Nishikawa K., Kikuchi S. Enhanced thromboxane A2 biosynthesis in the kidney of spontaneously hypertensive rats during development of hypertension. Eur J Pharmacol. 1981 Mar 26;70(3):247–256. doi: 10.1016/0014-2999(81)90157-6. [DOI] [PubMed] [Google Scholar]
  14. Stegmeier K., Pill J., Müller-Beckmann B., Schmidt F. H., Witte E. C., Wolff H. P., Patscheke H. The pharmacological profile of the thromboxane A2 antagonist BM 13.177. A new anti-platelet and anti-thrombotic drug. Thromb Res. 1984 Aug 15;35(4):379–395. doi: 10.1016/0049-3848(84)90230-5. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES